PSMA inhibitor-based radiopharmaceuticals for diagnosis and therapy of prostate cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
Mainz, Johannes Gutenberg-Universität Mainz, Dissertation, 2022
- Keyword
-
Therapeutics
Prostate--Cancer
Radiopharmaceuticals
Diagnosis
- Event
-
Veröffentlichung
- (where)
-
Mainz
- (who)
-
Universitätsbibliothek der Johannes Gutenberg-Universität Mainz
- (when)
-
2022
- Creator
- DOI
-
10.25358/openscience-6937
- URN
-
urn:nbn:de:hebis:77-openscience-032d49ad-e188-44a4-848e-db0f65afd6bf3
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
25.03.2025, 1:54 PM CET
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Grus, Tilmann
- Universitätsbibliothek der Johannes Gutenberg-Universität Mainz
Time of origin
- 2022
Other Objects (12)
Inhibitors of the prostate-specific membrane antigen (PSMA) for PET imaging and endoradiotherapy of prostate cancer
PSMA-targeting radiopharmaceuticals for prostate cancer Therapy: recent developments and future perspectives
Imaging and photodynamic therapy of prostate cancer using a theranostic PSMA-targeting ligand
DNA damage in blood leucocytes of prostate cancer patients during therapy with 177Lu-PSMA
Combination therapies to enhance the efficacy of PSMA-targeted radioligand therapy in prostate cancer
Development of PSMA inhibitors for molecular imaging and radio-guided surgery of prostate cancer
Development of inhibitors of the prostate specific membrane antigen (PSMA) for imaging and endoradiotherapy
Towards improving the efficacy of PSMA-targeting radionuclide therapy for late-stage prostate cancer - combination strategies
Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
Diagnostic value of additional 68Ga-PSMA-PET before 223Ra-dichloride therapy in patients with metastatic prostate carcinoma
Hematotoxicity and nephrotoxicity in prostate cancer patients undergoing radioligand therapy with [\(^177}\)Lu]Lu-PSMA I&T
⁶⁸Ga-PSMA PET for the assessment of metastatic prostate cancer
Inhibitors of the prostate-specific membrane antigen (PSMA) for PET imaging and endoradiotherapy of prostate cancer
PSMA-targeting radiopharmaceuticals for prostate cancer Therapy: recent developments and future perspectives
Imaging and photodynamic therapy of prostate cancer using a theranostic PSMA-targeting ligand
DNA damage in blood leucocytes of prostate cancer patients during therapy with 177Lu-PSMA
Combination therapies to enhance the efficacy of PSMA-targeted radioligand therapy in prostate cancer
Development of PSMA inhibitors for molecular imaging and radio-guided surgery of prostate cancer
Development of inhibitors of the prostate specific membrane antigen (PSMA) for imaging and endoradiotherapy
Towards improving the efficacy of PSMA-targeting radionuclide therapy for late-stage prostate cancer - combination strategies
Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
Diagnostic value of additional 68Ga-PSMA-PET before 223Ra-dichloride therapy in patients with metastatic prostate carcinoma
Hematotoxicity and nephrotoxicity in prostate cancer patients undergoing radioligand therapy with [\(^177}\)Lu]Lu-PSMA I&T
⁶⁸Ga-PSMA PET for the assessment of metastatic prostate cancer
Inhibitors of the prostate-specific membrane antigen (PSMA) for PET imaging and endoradiotherapy of prostate cancer
PSMA-targeting radiopharmaceuticals for prostate cancer Therapy: recent developments and future perspectives
Imaging and photodynamic therapy of prostate cancer using a theranostic PSMA-targeting ligand
DNA damage in blood leucocytes of prostate cancer patients during therapy with 177Lu-PSMA
Combination therapies to enhance the efficacy of PSMA-targeted radioligand therapy in prostate cancer
Development of PSMA inhibitors for molecular imaging and radio-guided surgery of prostate cancer
Development of inhibitors of the prostate specific membrane antigen (PSMA) for imaging and endoradiotherapy
Towards improving the efficacy of PSMA-targeting radionuclide therapy for late-stage prostate cancer - combination strategies
Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
Diagnostic value of additional 68Ga-PSMA-PET before 223Ra-dichloride therapy in patients with metastatic prostate carcinoma
Hematotoxicity and nephrotoxicity in prostate cancer patients undergoing radioligand therapy with [\(^177}\)Lu]Lu-PSMA I&T